Study type

Study type

Non-interventional study

Scope of the study

Disease epidemiology
Non-interventional study

Non-interventional study design

Case-control
Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(B01A) ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
(C09A) ACE INHIBITORS, PLAIN
ACE INHIBITORS, PLAIN
(C09C) ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
(M01A) ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

Medical condition to be studied

Hospitalisation
Nosocomial infection

Additional medical condition(s)

ICU admision,Mortality
Population studied

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

75000
Study design details

Main study objective

Assess whether prior consumption of certain medications (ACEIs, ARBs, ibuprofen…) conditions a greater susceptibility to infection by SARS-COV-2

Outcomes

Hospitalization by COVID-19

Data analysis plan

Multilevel logistic regression analysis will be performed, considering each stratum (a case and the controls with the matching variables) as an aggregation unit to estimate the odds ratio, and its 95% confidence interval (CI) for the risk of Covid- 19 associated with exposures of interest. Adjustments will be made for the above-reported covariates. Odds ratio trends will be tested, when feasible, according to the statistical significance of the regression coefficient of the recoded variable obtained by scoring the corresponding categories. Crude and adjusted estimates will be obtained for the effect of different therapies dispensed compared with the absence of any drug therapy.